| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Megna Michael R | Chief Accounting Officer | Sell | 17,647 | $26.69 | $470,998.43 | -35.2% | +23.5% | +112.7% | |
| May 7, 2025 | OGN Organon & Co. | Falcione Aaron | Chief Human Resources Officer | Buy | 5,500 | $8.77 | $48,235.00 | +9.6% | -4.1% | - | |
| May 7, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Paolini John F.51 | Chief Medical Officer | Sell | 200 | $27.00 | $5,400.00 | -0.3% | +23.5% | +112.7% | |
| May 7, 2025 | LFCR Lifecore Biomedical, Inc. \de\ | English Aron R.50 | 10% Owner | Sell | 41,091 | $7.05 | $289,869.36 | -0.8% | +3.6% | - | |
| May 6, 2025 | OGN Organon & Co. | Karp Daniel | Executive VP, Corp. Dev. | Buy | 3,500 | $8.24 | $28,828.10 | +8.1% | +5.9% | +45.6% | |
| May 6, 2025 | OGN Organon & Co. | Weaver Kirke | Gen. Counsel &Corp. Secy. | Buy | 8,045 | $9.21 | $74,054.23 | +18.1% | +5.9% | +45.6% | |
| May 5, 2025 | NBIX Neurocrine Biosciences Inc | Rastetter William H48 | Director | Sell | 30,000 | $110.20 | $3,305,952.00 | -44.5% | +16.7% | +23.1% | |
| May 5, 2025 | OGN Organon & Co. | Walsh Matthew M | Chief Financial Officer | Buy | 11,400 | $8.82 | $100,548.00 | +8.6% | +10.9% | +52.4% | |
| May 5, 2025 | OGN Organon & Co. | Ali Kevin | Chief Executive Officer | Buy | 34,000 | $8.81 | $299,370.00 | +13.7% | +10.9% | +52.4% | |
| May 5, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Patel Gautam | Director | Sell | 8,668 | $8.00 | $69,344.00 | -0.3% | +5.6% | +77.9% | |
| May 5, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Moat Ross | Chief Commercial Officer | Sell | 10,122 | $28.00 | $283,416.00 | -35.0% | +18.6% | +104.2% | |
| May 2, 2025 | DERM Journey Medical Corp | Maraoui Claude | President &CEO | Sell | 4,834 | $6.84 | $33,064.56 | -0.2% | +4.6% | -26.2% | |
| May 2, 2025 | DERM Journey Medical Corp | Benesch Joseph | CFO | Sell | 2,409 | $6.84 | $16,477.56 | -1.2% | +4.6% | -26.2% | |
| May 2, 2025 | DERM Journey Medical Corp | Alloush Ramsey | COO | Sell | 2,857 | $6.84 | $19,541.88 | -0.6% | +4.6% | -26.2% | |
| May 1, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $24.08 | $12,041.45 | -0.7% | -10.6% | -8.4% | |
| May 1, 2025 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 11,000 | $300.93 | $3,310,201.49 | -2.7% | -4.0% | +94.1% | |
| May 1, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | Chief Financial Officer | Sell | 88,395 | $26.56 | $2,347,335.10 | -52.2% | +8.4% | +99.2% | |
| May 1, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Moat Ross | Chief Commercial Officer | Sell | 87,269 | $25.96 | $2,265,339.03 | -82.3% | +8.4% | +99.2% | |
| Apr 30, 2025 | CPIX Cumberland Pharmaceuticals Inc | Krogulski Kenneth54 | Director | Buy | 1,035 | $4.48 | $4,635.30 | - | -27.7% | -13.3% | |
| Apr 30, 2025 | CPIX Cumberland Pharmaceuticals Inc | Kazimi A J59 | Chairman And CEO | Buy | 186 | $4.48 | $833.30 | - | -27.7% | -13.3% | |
| Apr 30, 2025 | CPIX Cumberland Pharmaceuticals Inc | Young Caroline52 | Director | Buy | 93 | $4.48 | $416.65 | - | -27.7% | -13.3% | |
| Apr 30, 2025 | CPIX Cumberland Pharmaceuticals Inc | Jones James53 | Director | Buy | 186 | $4.48 | $833.30 | - | -27.7% | -13.3% | |
| Apr 29, 2025 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 91,667 | $33.57 | $3,077,070.06 | -33.2% | +67.5% | -24.9% | |
| Apr 28, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 3,236 | $30.19 | $97,694.84 | -2.0% | +106.0% | -2.0% | |
| Apr 28, 2025 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 455 | $14.24 | $6,479.20 | -0.2% | +39.3% | +164.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.